Extended-release niacin or ezetimibe and carotid intima-media thickness.
about
The therapeutic potential of metal-based antimalarial agents: implications for the mechanism of actionNiacin for primary and secondary prevention of cardiovascular eventsColesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of actionLipoprotein(a) as a cardiovascular risk factor: current statusEzetimibe therapy: mechanism of action and clinical updateCardiovascular Imaging for the Primary Prevention of Atherosclerotic Cardiovascular Disease EventsNiacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?Origin and therapy for hypertriglyceridaemia in type 2 diabetesAspects of Exercise before or after Bariatric Surgery: A Systematic ReviewA review of the rationale for additional therapeutic interventions to attain lower LDL-C when statin therapy is not enoughBenefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetesNiacin, an old drug with a new twistRegression of atherosclerosis: insights from animal and clinical studiesNonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB CouncilGPR109A and vascular inflammationThe therapeutic role of niacin in dyslipidemia managementClinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trialsUtility of atherosclerosis imaging in the evaluation of high-density lipoprotein-raising therapies.LDL lowering in peripheral arterial disease: are there benefits beyond reducing cardiovascular morbidity and mortality?The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline.Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease.Segmental analysis of carotid arterial strain using speckle-tracking.Differential impacts of blood pressure and lipid lowering on regression of ventricular and arterial mass: the Stop Atherosclerosis in Native Diabetics Trial.Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms.[Distribution of carotid intima media thickness in men and women with and without coronary heart disease. Cross-sectional data of the Heinz Nixdorf Recall Study].The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk.Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.Treating diabetic dyslipidemia: What have we learnt from recent clinical trials?MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study.A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.The triple line pattern on carotid intima media thickness imaging and its relationship to cardiovascular risk factors in patients on lipid lowering therapy.To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?Management of hypertriglyceridemia in the diabetic patientPrimary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Influence of previous statin therapy on cholesterol-lowering effect of ezetimibe.The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?
P2860
Q20906133-FC7B5E2B-263D-4153-B141-B21B7C8CF8ADQ24203613-C44CDDB0-4ACA-47F6-9A55-8CE2E6EBA0B4Q24613405-C5E72593-0E86-4031-84B5-D34A8B7BD992Q24623225-B26A5110-612A-4907-93C1-DE4AAEC51A25Q24630302-EE14CF68-B535-47F0-B3E7-601E000C5CD8Q26795419-0DA8B95C-A3CA-4130-8305-1DBAA5E93795Q26799534-C390822F-C6EA-46AB-9EBE-3DD5C71183C5Q26824004-F0AF334B-E745-4D62-991C-70AF92F6949EQ26824049-B3B55F4D-2E08-4825-8EA7-08024AE3A352Q26824249-2ECF4CA7-7ED8-42A7-BBAA-D762A54E5868Q26853571-11F78F58-109C-45B1-A5FA-06121B182406Q27002774-D0A44516-6964-4E38-8F2E-05647B2EC243Q27028112-889981F0-1FD6-4E8D-9F50-04FA6F86F84CQ28084156-38162CBC-F3EC-4FE2-AA71-E48089066B41Q28287747-63116E6C-3759-4857-8F1D-B1CC43EB24A9Q28304559-6DD1F65B-CB38-4586-AEE0-744401C64C46Q28546769-81135A7E-00BE-4AD2-BD37-6A2A38403E62Q30401532-C4DD5B90-0EA2-4FED-84D2-D57364548729Q30422549-35B67B64-01E3-4DE7-A4F5-FF13AA47FB03Q30425097-48640918-B87B-4797-B564-D1282E6458CEQ30430614-2C833AA3-BA3B-4D91-9A38-A37330EDE530Q30461867-CD2DBF96-2980-4485-8FB1-AFFBF794F27BQ30464117-33C0E9BE-EBF5-4947-9633-D9CED3BEC06DQ30519552-A6DAFD74-5DD6-45F6-B057-32DA0E4132FEQ30578465-9FD8EDC2-88F6-4E9C-8E7D-AECBCAB0795AQ30662013-BC7D9876-C14C-46F8-B99F-3CA75BDFF71FQ31053398-272DC911-CBF4-45B9-8260-E7A76CDA2D85Q33537687-7D0649D7-6F43-4101-B549-54E4EA3B5A65Q33585474-4386B3C9-1CB7-47A8-8758-FDC87EE968F1Q33631184-A4D0E333-8EF1-4A97-BD36-2B0CC9E1AE99Q33765072-924A91DC-3DDE-49EB-A80F-9A4A56197673Q33776194-F5C966B1-CDEF-42CB-BD5E-D4149153983DQ33776230-6BC1185A-F529-4E91-B5EB-D32052CC313EQ33802196-C1DF68CA-9ED6-4CDE-BF81-6EFB6396C81FQ33817761-FA1D4F4A-6D2D-405C-91C6-8DC0F02B82DCQ33820018-0C8946D4-0B40-4CD5-B9F0-8E8A578E77F7Q33935729-1D952F8D-80AD-4500-876C-D6D30C185DFEQ33972551-3D612B13-07F4-4679-9BE9-4D0BB0EB4FCFQ33984025-37F5C29E-339E-4211-92F4-650B66BDD549Q33993233-2AB925BC-82DF-454C-9A28-B3850497C405
P2860
Extended-release niacin or ezetimibe and carotid intima-media thickness.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Extended-release niacin or ezetimibe and carotid intima-media thickness.
@ast
Extended-release niacin or ezetimibe and carotid intima-media thickness.
@en
type
label
Extended-release niacin or ezetimibe and carotid intima-media thickness.
@ast
Extended-release niacin or ezetimibe and carotid intima-media thickness.
@en
prefLabel
Extended-release niacin or ezetimibe and carotid intima-media thickness.
@ast
Extended-release niacin or ezetimibe and carotid intima-media thickness.
@en
P2093
P356
P1476
Extended-release niacin or ezetimibe and carotid intima-media thickness
@en
P2093
Allen J Taylor
Eric J Stanek
Len Griffen
Mark Turco
Michael Miller
Neil J Weissman
Patrick J Devine
P304
P356
10.1056/NEJMOA0907569
P407
P577
2009-11-15T00:00:00Z